Defactinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 112 publications
Corrigendum to 'Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer' [International Journal of Gynecological Cancer Volume 36 Issue 5 (2026) 104635].
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 12, 2026
An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Journal: Expert review of anticancer therapy
Published: April 30, 2026
Electrospun Hyaluronic Acid/Polyvinyl Alcohol Nanofibers Encapsulating Defactinib as Bioactive Dressings for Burn Wound Therapy.
Journal: ACS applied bio materials
Published: March 12, 2026
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.
Journal: Pharmacological research
Published: January 20, 2026
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review.
Journal: British journal of pharmacology
Published: January 16, 2026
Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: December 12, 2025
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Future oncology (London, England)
Published: December 12, 2025
Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma - A case report.
Journal: Gynecologic oncology reports
Published: November 19, 2025
RPRD1A drives lenvatinib resistance in hepatocellular carcinoma via the ITGA5-FAK signaling axis.
Journal: Molecular biomedicine
Published: November 07, 2025
Unmet needs and emerging therapeutics in low-grade serous ovarian carcinoma: from chemoresistance to precision medicine.
Journal: Future oncology (London, England)
Published: November 05, 2025
Last Updated: 06/30/2026